NephroGenex: Annual Report 2014 (Nephrogenex) - Mar 27, 2015 - Anticipated expiry of patent for methods of use in Jun 2024; Anticipated expiries of additional patents between 2016 and 2035; Anticipated expiry of patents in US and EU related to analogs and their uses as therapeutics in 2027; Anticipated expiry of patents for inhibiting oxidative modification of proteins or treating atherosclerosis in a non hyperglycemic mammal in US by 2016 and ex-US by 2019; Anticipated expiry of patents for treating diabetic neuropathy in US by 2016 and ex-US by 2019; Anticipated expiry of patents licensed by KUMC for method of treatment of diabetic nephropathy, proteinuria or albuminuria associated with elevated blood sugar levels, retinopathy or neurodegenerative disease by 2016; Anticipated patent expiry for method of use in treating diabetic nephropathy in US, EU and Canada in 2024
Anticipated patent expiry • Renal Disease
|